Bladder cancer

1 INTRODUCTION 3 -- 1.1 BACKGROUND 3 -- 1.2 OVERALL OBJECTIVES 3 -- 1.3 RESEARCH QUESTION 3 -- 2 METHODOLOGY 4 -- 2.1 SEARCH STRATEGY: DATABASES AND DATE LIMITS 4 -- 2.1.1 Electronic medical databases 4 -- 2.1.2 Handsearch on institutional websites 6 -- 2.2 SEARCH RESULTS AND PRIMARY SELECTION .6 -- 2.3 THE AGREE INSTRUMENT 8 -- 3 CRITICAL APPRAISAL OF RECENT GUIDELINES .9 -- 3.1 HAUTE AUTORITÉ DE SANTÉ – 2010 .9 -- 3.2 ITALIAN UROLOGICAL ASSOCIATION – 2010 9 -- 3.3 INTERNATIONAL BLADDER CANCER GROUP – 2011 10 -- 3.4 FRENCH UROLOGICAL ASSOCIATION CANCER COMMITTEE (CCAFU) – 2013 .10 -- 3.5 ALBERTA PROVINCIAL GENITOURINARY TUMOUR TEAM – 2013 (MUSCLE-INVASIVE CANCER) 11 -- 3.6 ALBERTA PROVINCIAL GENITOURINARY TUMOUR TEAM – 2013 (NON-MUSCLE-INVASIVE CANCER) 12 -- 3.7 EUROPEAN ASSOCIATION OF UROLOGY – 2014 (NON-MUSCLE-INVASIVE CANCER) 13 -- 3.8 EUROPEAN ASSOCIATION OF UROLOGY – 2014 MUSCLE-INVASIVE CANCER) 14 -- 3.9 NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) – 2015 14 -- 3.10 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) – 2015 15 -- 3.11 DISCUSSION 17 -- 4 THE NICE 2015 GUIDELINE ON DIAGNOSIS AND MANAGEMENT OF BLADDER CANCER 18 -- 4.1 THE “GUIDANCE” SECTION OF NICE’S GUIDELINE 18 -- 4.2 THE “TOOLS AND RESOURCES” SECTION OF NICE’S GUIDELINE .19 -- 4.3 THE “INFORMATION FOR THE PUBLIC” SECTION OF NICE’S GUIDELINE .19 -- 5 CONCLUSION .20